Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide for NAFLD in Obesity and Type 2 Diabetes
NCT05813249Phase 4Completed
- Sponsor
- Zagazig University
- Start
- Feb 2023
- Primary completion
- Feb 2024
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 4 trial of semaglutide in non-alcoholic fatty liver disease (NAFLD), sponsored by Zagazig University. Started Feb 2023; status: completed.
02
Drugs
03
Conditions
non-alcoholic fatty liver disease (NAFLD)
Beyond the preview
Go deeper on NCT05813249.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05813249.